Xuanzhu Biopharma Receives NMPA Approval for Phase III Trial of Anaprazole-Based Quadruple Therapy Against H. pylori
Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) announced it has received regulatory clearance from the National...
Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) announced it has received regulatory clearance from the National...
Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) announced completion of full enrollment for its Phase III...
Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) announced that the interim analysis of the Phase III BRIGHT‑3...